Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.55 |
| ▸ | ABL1 | P00519 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094120 | 1.00 | MET (0.55) | METABL1KMT2ACYP3A4AURKB | |
| SCHEMBL3093085 | 1.00 | MET (0.55) | METABL1KMT2ACYP3A4AURKB | |
| SCHEMBL3102114 | 0.96 | MET (0.51) | METABL1KMT2ACYP3A4AURKB | |
| SCHEMBL3101966 | 0.94 | ABL1 (0.54) | METABL1KMT2ACYP3A4AURKB | |
| SCHEMBL3104547 | 0.94 | ABL1 (0.57) | METABL1KMT2ACYP3A4AURKB | |
| SCHEMBL3102959 | 0.93 | MET (0.51) | METABL1 | |
| SCHEMBL3104924 | 0.93 | ABL1 (0.54) | METABL1KMT2ACYP3A4AURKB | |
| SCHEMBL3114877 | 0.93 | MET (0.50) | METABL1 | |
| SCHEMBL3104505 | 0.93 | ABL1 (0.53) | METABL1POLB | |
| SCHEMBL3788533 | 0.91 | ABL1 (0.54) | METABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188078-B2 | 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20100273793-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-10-28 | — | — | US | disclosed |
| EP-2205568-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009087305-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS | SANOFI-AVENTIS (FR) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273793-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS | MET, ALK, JAK2 | MET 1/4885ABL1 4/4885KMT2A 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.